OmniStocks

$ENZC 💥MASSIVE PR 💥 1️⃣The purpose of the amended OTC Annual Report filed today is to include the audited financial statements  2️⃣With the completed sale of the operating subsidiaries, the Company will no longer be the source of news on the progress and developments of VIRO or BGEN. 💥💥As a party to the business combination agreement with SAGA the Company can report that the transaction is #COMPLETE💥💥 3️⃣The 45 million shares of SAGA stock have been received by the sellers and the Company is in the process of completing the regulatory required paperwork to declare and distribute 36 million shares to the ENZC equity holders (~1:250 Conversion) 4️⃣The African clinical trial is expected to conclude with a final report by the end of 2024 5️⃣The Clinical Trials will now include testing on patients with cirrhosis; cancer patients after receiving chemotherapy and radiotherapy treatments, HIV and all diseases in which there is an immune system decline 6️⃣The previously announced clinical trials on Diabetes in Bulgaria remain in progress 7️⃣Additionally, VIRO has developed a new formulation to produce IPF Immune in a pill form while adding a vitamin C component. 💊 8️⃣ Agressive marketing campaign that was being negotiated and developed featuring a former #NFL    player as spokesperson in IPF's first video presentation and the launch of VIRO's website 🔥🔥🔥😱😱😱 #WINNING🏆